Novartis India Ltd has secured exclusive rights to distribute a key ophthalmology portfolio in India through a new agreement with Novartis Healthcare Private Limited (NHPL). The company will pay an upfront consideration of ₹10 crore for the rights.

The agreement, dated September 8, 2026, grants Novartis India the authority to exclusively promote and distribute NHPL’s retina products. This move is expected to support the company’s entry into the ophthalmology therapy area and expand its commercial offerings.

Deal Details

The transaction involves specific products and terms as disclosed under SEBI Listing Regulations.

The portfolio comprises Accentrix® and Pagenax®, targeting the retina segment. The disclosure confirms that there is no shareholding interest between the parties, and the transaction does not constitute a related-party deal.

Strategic Context

This partnership marks a strategic expansion for Novartis India into the ophthalmology space. By acquiring exclusive promotion and distribution rights, the company aims to leverage NHPL’s existing product strength in the retina category. The upfront payment of ₹10 crore secures these rights for the Indian territory, aligning with broader efforts to diversify its commercial portfolio.

Source: Exclusive content

Novartis India Limited has acquired the trademarks ‘Minipress’ and ‘Minipres’ along with related intellectual property rights from Pfizer Inc. USA and Pfizer Products Inc. USA. The transaction was approved by the Board of Directors on September 7, 2026.

The total aggregate consideration for the acquisition is ₹1,250.001 crore. The company executed an asset purchase agreement and trademark assignment deeds on September 7, 2026. The signing and closing of the transaction occurred simultaneously.

Transaction Details

The acquisition involves the assignment of trademarks registered in India. The counterparty is not related to the promoter or promoter group of Novartis India. The transaction is not classified as a related party transaction.

Product Context

According to IQVIA MAT July’26 data, Minipress XL recorded revenue of ₹228.6 crore. The product has grown at a CAGR of 6.3% over the past four years. The broader category grew at a 9% CAGR during the same period. Minipress XL contains prazosin and is indicated for treating hypertension and managing urinary symptoms of benign prostatic hyperplasia (BPH).

What the Numbers Show

The acquisition price implies a significant premium over recent run-rate sales. With a consideration of ₹1,250.001 crore against reported revenue of ₹228.6 crore, the deal values the brand at approximately 5.5 times its trailing twelve-month revenue based on the provided IQVIA data. This suggests Novartis is paying for long-term market share stability and brand equity in the hypertension segment rather than immediate cash flow generation.